Ignite Creation Date:
2024-05-06 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06238401
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-02
First Post:
2024-01-17
Brief Title:
Study of ACR246 in Advanced Solid Tumors
Sponsor:
Hangzhou Adcoris Biopharmacy Co Ltd
Organization:
Hangzhou Adcoris Biopharmacy Co Ltd
Study Overview
Official Title:
An Open-label Multicenter Dose-escalation and Cohort Expansion Phase IIIa Clinical Study to Evaluate the Safety Tolerability Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of the study is to evaluate the safety and tolerability of ACR246 in patients with advanced solid tumors to determine the maximum tolerated dose MTD and Phase II recommended dose RP2D of ACR246
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None